NCT06739486Not yet recruiting
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
Source: ClinicalTrials.gov · Last updated 18 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
evaluate the effectiveness of sodium-glucose cotransporter-2 (SGLT.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 17 Nov 2024
- Start date
- 20 Dec 2024
- Primary completion date
- 20 Nov 2025
- Lead sponsor
- Assiut University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06739486
What you commit to
- Study type: Observational
- Planned participants: 100
- From 20 Dec 2024 to the primary completion date, 20 Nov 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- any cause of liver affection (hepatitis, autoimmune…etc)
Other
- alcohol drinker
- patients with kidney function affection
Who the study is looking for
- age \>18 years
- both sex
Age in the registry: 18 years to 65 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.